Omega-3 Fatty Acid Composition with 17-HDHA and 18-HEPE for Inflammation Resolution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective solutions for resolving chronic inflammation, which is a hallmark of various diseases such as rheumatoid arthritis, atherosclerosis, and cancer, as they fail to efficiently manage the transition from acute to chronic inflammatory responses.
Innovation Solution
A polyunsaturated fatty acid composition comprising 20% to 95% Omega-3 fatty acids, 0.0005% to 1% 17-HDHA and 18-HEPE, and optionally DPA, administered in a capsule or dosage unit, is used to enhance phagocytic activity, promote macrophage polarization, and resolve inflammation through supercritical fluid extraction and distillation processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-inflammatory treatments are used, then inflammation is suppressed, but the resolution process is impaired and chronic inflammation persists
Solution Approach 1:
The patent changes the chemical parameters of the fatty acid composition by specifying precise ratios of Omega-3 fatty acids (20-95%), 17-HDHA (0.0005-1%), and 18-HEPE (0.0005-1%). This parameter optimization enables the composition to promote inflammation resolution rather than suppression, addressing the contradiction between effective anti-inflammatory action and proper resolution mechanisms.
Solution Approach 2:
The patent creates a composite fatty acid composition combining multiple specific components (Omega-3 fatty acids, 17-HDHA, and 18-HEPE) in defined proportions. This composite approach enables synergistic effects that promote both anti-inflammatory action and resolution, overcoming the limitation of single-component treatments that fail to resolve chronic inflammation.
2Reliability
If Omega-3 fatty acid supplementation is increased, then anti-inflammatory effect is enhanced, but the composition complexity increases
Solution Approach 1:
The patent optimizes the concentration parameters of individual components within the fatty acid composition. By specifying precise ranges (Omega-3: 20-95%, 17-HDHA: 0.0005-1%, 18-HEPE: 0.0005-1%), the patent achieves enhanced anti-inflammatory effect while maintaining manageable composition complexity through quantitative control rather than qualitative complexity.
3Reliability
If specialized pro-resolving mediators are introduced, then inflammation resolution is improved, but the manufacturing process becomes more complex
Solution Approach 1:
The patent incorporates 17-HDHA and 18-HEPE as pre-formed specialized pro-resolving mediators in the fatty acid composition during manufacturing. This preliminary inclusion of resolution mediators eliminates the need for complex post-processing to generate them, thereby improving inflammation resolution while maintaining manufacturing simplicity.
Solution Approach 2:
The patent merges the functions of anti-inflammatory fatty acids and pro-resolving mediators into a single integrated composition. By combining Omega-3 fatty acids with 17-HDHA and 18-HEPE in defined ratios, the patent achieves both anti-inflammatory and resolution functions simultaneously, avoiding the need for separate treatment protocols and simplifying manufacturing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively elevates SPM levels, increases phagocytic activity, and promotes a pro-resolution phenotype in macrophages, thereby aiding in the resolution of inflammation and improving tissue integrity in diseases with inflammatory components.
Implementation Method 1
Processes of obtaining and using the compositions are also provided
Implementation Method 2
Processes of obtaining and using the compositions are also provided
Data Source
AI summary
The present invention relates to a polyunsaturated fatty acid composition comprising Omega-3 fatty acids, 17-HDHA and 18-HEPE. The composition can furthermore comprise DPA and/or an acceptable carrier and can be present in a capsule or other suitable dosage unit. The invention also relates to the process of obtaining the composition and methods for using same.